The cellular phenotype of AZ703, a novel selective imidazo[1,2-<i>a</i>]pyridine cyclin-dependent kinase inhibitorKate F. Byth(AstraZeneca (United Kingdom)), Andrew P. Thomas(AstraZeneca (United Kingdom))Molecular Cancer TherapeuticsMarch 1, 200610.1158/1535-7163.mct-05-0205Cited by 48SaveCiteExport RISWatch citationsRelated PapersSynergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma|Oncotarget|2014|54